Navigation Links
Einstein scientists discover how protein crucial for motion is synthesised at the right place in the cell

Researchers at the Albert Einstein College of Medicine and the German Cancer Research Institute have shown how protein synthesis is targeted to certain regions of a cell--a process crucial for the cellular motility that governs nerve growth, wound healing and cancer metastasis. Their study appears in the November 24 issue of the journal Nature.

Led by Drs. Robert Singer and Dr Stefan Huettelmaier, the research team focused on migrating fibroblast cells important in wound healing. To move towards a wound, these cells manufacture the protein actin, which polymerizes into long filaments that push the cell's membrane outward to form protrusions.

The team's previous work showed how newly formed actin messenger RNA molecules find their way to the cell's periphery: A protein called ZBP1 binds to the messenger RNA and "escorts" it out of the fibroblast nucleus and into the cytoplasm. On reaching the cell's periphery, the messenger RNA is translated into actin protein responsible for cell motility.

This new study reveals another key role for ZBP1: Not only does ZBP1 bind to actin messenger RNA and guide it to the cell's periphery, but it also helps regulate where in the cell the messenger RNA is translated into actin.

"The ZBP1 bound to actin's messenger RNA acts like a lock to prevent it from being translated into protein before reaching its destination," explains Dr. Singer. "On arriving at the cell periphery, the messenger RNA/ZBP1 complex encounters an enzyme, the protein kinase Src, which is active only in that part of the cell. Src adds a phosphate group to ZBP1 close to where it binds to messenger RNA, and this phosphorylation reaction detaches ZBP1 from the actin messenger RNA--unlocking the messenger RNA so it can now be translated into the actin protein that makes cell movement possible."

Understanding how actin synthesis is spatially regulated in motile cells could lead to new cancer therapies. "In cancer," says Dr. Singer , "we know that expression of ZBP1 correlates with benign tumors, while suppression of ZBP1 is associated with metastasis--when motile cancer cells break off from the primary tumor and invade other areas of the body. So a drug that could force tumor cells to express ZBP1 might prevent cancers from spreading."

In addition to Dr. Singer, other Einstein researchers involved in the study are Dr. John Condeelis, professor and co-chair with Dr. Singer of Einstein's Department of Anatomy and Structural Biology, Daniel Zenklusen, Mike Lorenz, XiuHua Meng, and Jason Dictenberg of that department, Gary J. Bassell of the Department of Neuroscience at Einstein, and Dr. Marcell Lederer, now in Dr. Huettelmaier's laboratory of Martin-Luther-University of Halle, Germany.


'"/>

Source:Albert Einstein College of Medicine


Related biology news :

1. Einstein researchers identify new way that bacteria develop resistance to antibiotics
2. Study by Einstein researchers could lead to a novel strategy for treating obesity
3. Einstein researchers take the pulse of a gene in living cells
4. Einstein researchers demonstrate a novel approach to treating AIDS
5. Einsteins tea leaves inspire new blood separation technique
6. Wisconsin scientists grow critical nerve cells
7. UCSB scientists probe sea floor venting to gain understanding of early life on Earth
8. UAB scientists discover the origin of a mysterious physical force
9. Fox Chase Cancer Center scientists identify immune-system mutation
10. Weizmann Institute scientists develop a new approach for directing treatment to metastasized prostate cancer in the bones.
11. U-M scientists find genes that control growth of common skin cancer
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/9/2016)... , June 9, 2016  Perkotek an innovation leader in attendance control systems is ... log work hours, for employers to make sure the right employees are actually signing ... http://photos.prnewswire.com/prnh/20160609/377486LOGO ... ... ...
(Date:6/7/2016)... -- Syngrafii Inc. and San Antonio Credit Union (SACU) ... Syngrafii,s patented LongPen™ eSignature "Wet" solution into SACU,s ... in greater convenience for SACU members and operational ... document workflow and compliance requirements. Logo ... Highlights: ...
(Date:6/2/2016)... The Department of Transport Management (DOTM) of ... project, for the , Supply and Delivery of ... Infrastructure , to Decatur , ... Management Solutions. Numerous renowned international vendors participated in the tendering ... selected for the most compliant and innovative solution. The contract ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) ... precise treatments and faster cures for prostate cancer. Members of the Class of ... 15 countries. Read More About the Class of 2016 ... ... ...
(Date:6/23/2016)... , June 23, 2016   EpiBiome , ... secured $1 million in debt financing from Silicon Valley ... up automation and to advance its drug development efforts, ... new facility. "SVB has been an incredible ... the services a traditional bank would provide," said Dr. ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
(Date:6/23/2016)... 2016 Apellis Pharmaceuticals, Inc. today announced ... of its complement C3 inhibitor, APL-2. The trials ... dose studies designed to assess the safety, tolerability, ... in healthy adult volunteers. Forty subjects ... single dose (ranging from 45 to 1,440mg) or ...
Breaking Biology Technology: